Topical Ketamine 10% for Neuropathic Pain in Spinal Cord Injury Patients: An Open-Label Trial.
Topical ketamine, an N-methyl-D-aspartate antagonist, has been shown to be effective in certain neuropathic pain syndromes. The objective of this study was to determine the efficacy of topical ketamine in spinal cord injury patients with neuropathic pain. An open label trial enrolled five subjects at an outpatient rehabilitation hospital with traumatic spinal cord injuries who had neuropathic pain at or below the level of injury. Subjects applied topical ketamine 10% three times a day for a two-week duration. Subjects recorded their numerical pain score-ranging from 0 to 10, with 0 representing "no pain, 5 representing "moderate pain," and 10 being described as "worst possible pain"-in a journal at the time of application of topical ketamine and one hour after application. Using a numerical pain scale allows for something as subjective as pain to be given an objective quantification. Subjects also recorded any occurrence of adverse events and level of satisfaction. All five subjects had a decrease in their numerical pain scale by the end of two weeks, ranging from 14% to 63%. The duration ranged from one hour in one subject to the next application in other subjects. There were no adverse effects. Overall, four out of the five subjects stated they were satisfied. Topical ketamine 10% is an effective neuropathic pain medicine in patients with spinal cord injuries; however, further studies need to be done with a placebo and larger sample size.
University of Chicago/Schwab Rehab Hospital, Chicago, Illinois. JRabil@gmail.com.
Joseph
J
Rabi
University of Chicago/Schwab Rehab Hospital.
Joshua
J
Minori
Midwestern University/Chicago College of Osteopathic Medicine, Palos Heights, Illinois.
Hasan
H
Abad
Schwab Rehabilitation Hospital, Chicago, Illinois.
Ray
R
Lee
Department of Orthopedic Surgery and Rehabilitation Medicine, Schwab Rehabilitation Hospital, University of Chicago, Chicago, Illinois.
Michelle
M
Gittler
D000279:Administration, Cutaneous; D000328:Adult; D000700:Analgesics / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007649:Ketamine / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D010147:Pain Measurement; D058748:Pain Perception / Q000187:drug effects; D017288:Pain Threshold / Q000187:drug effects; D017060:Patient Satisfaction; D013119:Spinal Cord Injuries / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D000700:Analgesics; D007649:Ketamine